Keith A. Ching

15.2k citations

45 papers · 8.8k indexed · 4 hit papers · h-index 24

Molecular Biology top 0.5%
- Renal and related cancers 5
- Gene expression and cancer classification 4
- Genomics and Chromatin Dynamics 4
Cancer Research top 2%
Genetics top 1%
Immunology top 2%
- Immune Cell Function and Interaction 4
Aging top 5%
Pulmonary and Respiratory Medicine
- Renal cell carcinoma treatment 8
- Ferroptosis and cancer prognosis 5
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 4
Oncology
- CAR-T cell therapy research 4

Co-authors: M. Cooke John R. Walker Andrew I. Su Tim Wiltshire John B. Hogenesch Bing Ren Roland D. Green Serge Batalov
Cited by: Molecular Biology Cancer Research Genetics
Journals: Cancer Research (5 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Keith A. Ching

44 papers receiving 8.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2007 Cell
2007 Nature Genetics
2004 Proceedings of the National Academy of Sciences
2002 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Keith A. Ching

Since Specialization

Citations

This map shows the geographic impact of Keith A. Ching's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith A. Ching with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith A. Ching more than expected).

Fields of papers citing papers by Keith A. Ching

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith A. Ching. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith A. Ching. The network helps show where Keith A. Ching may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Keith A. Ching, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keith A. Ching Line = papers co-authored together Keith A. Ching links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term mortality outcomes of southeast asian patients with aortic stenosis European Heart Journal ·永田莉奈,Alex Hwong‐Ruey Leow,Keith A. Ching,Farhan Muhareb,Nicholas Chew,William Kong,Tiong‐Cheng Yeo,Ching‐Hui Sia,Kian Keong Poh	2024	0
2	A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes Annals of Hematology ·Mikkael A. Sekeres,Michael Schuster,Magalie Joris,Jürgen Krauter,Johan Maertens,Dimitri Breems,Emmanuel Gyan,Tibor Kovacsovics,Amit Verma,Paresh Vyas,Eunice S. Wang,Keith A. Ching,Thomas O’Brien,Corrado Gallo Stampino,Weidong Wendy,Arthur J. Kudla,Geoffrey Chan,Amer M. Zeidan	2022	11
3	Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial Nature Communications ·Robert J. Motzer,Jean‐François Martini,Xinmeng Jasmine Mu,Michael Staehler,Daniel J. George,Olga Valota,Xun Lin,Hardev Pandha,Keith A. Ching,Alain Ravaud	2022	7
4	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial Nature Medicine ·Thomas Powles,Srikala S. Sridhar,Yohann Loriot,Joaquim Bellmunt,Xinmeng Jasmine Mu,Keith A. Ching,Jie Pu,Cora N. Sternberg,Daniel P. Petrylak,Rosa Tambaro,Louis Marie Dourthe,Carlos Álvarez-Fernández,Maureen J.B. Aarts,Alessandra di Pietro,Petros Grivas,Craig B. Davis	2021	74
5	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial ESMO Open ·Toni K. Choueiri,James Larkin,Sumanta K. Pal,Robert J. Motzer,Brian I. Rini,B. Venugopal,B. Yа. Alekseev,Hideaki Miyake,Gwénaëlle Gravis,Mehmet Asım Bilen,Seetharaman Hariharan,A. Chudnovsky,Keith A. Ching,Xinmeng Jasmine Mu,Mariangela Mariani,Paul B. Robbins,Bo Huang,Alessandra di Pietro,Laurence Albigès	2021	34
6	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas Clinical Cancer Research ·Ajay K. Gopal,Ronald Levy,Roch Houot,Sandip Pravin Patel,Leslie Popplewell,Caron A. Jacobson,Xinmeng Jasmine Mu,Shibing Deng,Keith A. Ching,Ying Chen,Craig B. Davis,Bo Huang,Kolette D. Fly,Aron D. Thall,Adrian Woolfson,Nancy L. Bartlett	2020	45
7	699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers Annals of Oncology ·Thomas Powles,Yohann Loriot,Joaquim Bellmunt,Cora N. Sternberg,Srikala S. Sridhar,Daniel P. Petrylak,Rosa Tambaro,Louis-Marie Dourthe,Carlos Álvarez-Fernández,Mihriban DEMİR,Xinmeng Jasmine Mu,Keith A. Ching,Jie Pu,Satrajit Roychoudhury,Craig B. Davis,Alessandra di Pietro,Petros Grivas	2020	14
8	Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling Cell Reports ·Patrick J Metz,Keith A. Ching,Tao Xie,И. С. Казловский,Sherry Niessen,John H. Tatlock,Kristen Jensen-Pergakes,Brion W. Murray	2020	28
9	Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) Annals of Oncology ·Laurence Albigès,Brian I. Rini,John B.A.G. Haanen,Robert J. Motzer,C. Kollmannsberger,Sylvie Négrier,Franco Nolè,Jens Bedke,Mehmet Asım Bilen,Paul Nathan,Yoshihiko Tomita,Bin Huang,Keith A. Ching,A. Chudnovsky,Paul B. Robbins,Alessandra di Pietro,Despina Thomaidou,Toni K. Choueiri	2019	16
10	PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor Clinical Cancer Research ·Kai Wang,Qin Zhang,Danan Li,Keith A. Ching,Cathy Zhang,Xianxian Zheng,Mark Ozeck,Stephanie Shi,Xiaorong Li,Hui Wang,Paul A. Rejto,James G. Christensen,Peter Olson	2015	122
11	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma Genomics ·Julio Fernandez-Banet,Nikki P. Lee,Kin Chan,Huan Gao,Xiao Liu,Wing‐Kin Sung,Winnie Tan,Sheung Tat Fan,Ronnie T.P. Poon,Shiyong Li,Keith A. Ching,Paul A. Rejto,Mao Mao,Zhengyan Kan	2014	44
12	Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871) Molecular Cancer Therapeutics ·Adam Pavlı́c̀ek,Maruja E. Lira,Nathan V. Lee,Keith A. Ching,Jingjing Ye,Joan Cao,Richard H. Böhning,Kenneth E. Hook,Mark Ozeck,Stephanie T. Shi,Jing Yuan,Xianxian Zheng,Paul A. Rejto,Julie L.C. Kan,James G. Christensen	2013	31
13	An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 Molecular Cancer Therapeutics ·Kenneth E. Hook,Richard H. Böhning,Maruja E. Lira,Keith A. Ching,Nathan V. Lee,Joan Cao,Jing Yuan,Jingjing Ye,Mark Ozeck,Stephanie T. Shi,Xianxian Zheng,Paul A. Rejto,Julie L.C. Kan,James G. Christensen,Adam Pavlı́c̀ek	2012	77
14	A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation PLoS ONE ·Nathan V. Lee,Maruja E. Lira,Adam Pavlı́c̀ek,Jingjing Ye,Dan A. Chrisman,Shubha Bagrodia,Sreesha P. Srinivasa,Yongjun Zhao,Samuel Aparício,Paul A. Rejto,James G. Christensen,Keith A. Ching	2012	40
15	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer Molecular Cancer Therapeutics ·Lily Vo,Keith A. Ching,Julie L.C. Kan,Hwang-Phill Kim,Sae‐Won Han,Seock‐Ah Im,Tae‐You Kim,James G. Christensen,Do‐Youn Oh,Yung‐Jue Bang	2011	58
16	Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency Cell Research ·R. David Hawkins,Gary C. Hon,Chuhu Yang,Jessica Antosiewicz‐Bourget,足利誠,大黒俊哉,Sarit Klugman,Keith A. Ching,Lee Edsall,Zhen Ye,Samantha Kuan,Pengzhi Yu,Hui Liu,Xinmin Zhang,Roland D. Green,Victor V. Lobanenkov,Ron Stewart,James A. Thomson,Bing Ren	2011	72
17	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clinical Cancer Research ·Ivo Meinhold‐Heerlein,Dirk Bauerschlag,Yingyao Zhou,Lisa M. Sapinoso,Keith A. Ching,Henry F. Frierson,Karen Bräutigam,Jalid Sehouli,Elmar Stickeler,Dominique Könsgen,Felix Hilpert,Constantin S. von Kaisenberg,Jacobus Pfisterer,Thomas Bauknecht,W. Jonat,Norbert Arnold,Garret M. Hampton	2007	41
18	A gene atlas of the mouse and human protein-encoding transcriptomesbreakdown → Proceedings of the National Academy of Sciences ·Andrew I. Su,Tim Wiltshire,Serge Batalov,Hilmar Lapp,Keith A. Ching,David E. Block,Jie Zhang,Mateus Huang Lopes,J. Soliński,Gabriel Kreiman,M. Cooke,John R. Walker,John B. Hogenesch	2004	2820
19	Emt/Itk Associates with Activated TCR Complexes: Role of the Pleckstrin Homology Domain The Journal of Immunology ·Keith A. Ching,Yuko Kawakami,Toshiaki Kawakami,Constantine D. Tsoukas	1999	52
20	Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation Journal of Virology ·Melissa C. Stoppler,Keith A. Ching,Hubert Stöppler,Kevin Clancy,Richard Schlegel,Joseph P. Icenogle	1996	129

About Keith A. Ching

Keith A. Ching is a scholar working on Hepatology, Oncology and Molecular Biology, having authored 45 papers that have together received 8.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (8 papers), Ferroptosis and cancer prognosis (5 papers), Renal and related cancers (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Gene expression and cancer classification (4 papers), Genomics and Chromatin Dynamics (4 papers), CAR-T cell therapy research (4 papers) and Immune Cell Function and Interaction (4 papers). The work is most often cited by research in Molecular Biology (6.6k citations), Cancer Research (989 citations) and Genetics (1.4k citations). Keith A. Ching has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include M. Cooke, John R. Walker, Andrew I. Su, Tim Wiltshire, John B. Hogenesch, Bing Ren, Roland D. Green, Serge Batalov, Hilmar Lapp and David E. Block. Their work appears in journals such as Cancer Research, Annals of Oncology, Journal of Clinical Oncology, Molecular Cancer Therapeutics and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact